ATLANTA--(BUSINESS WIRE)--NeurOp, Inc. today announced that Robert Zaczek, Ph.D., has been named its chief scientific officer, a new role for the company. He will oversee the company’s drug research, which is focused on NMDA receptor modulation for the treatment of depression, neuropathic pain, ischemia (stroke), schizophrenia and other central nervous system disorders.
